EQS-Adhoc

Lists of candidates for the board of directors at the AGM 2021 - Seite 2

In particular pursuant to art. 106, paragraph 4, of Law-Decree n. 18 dated March 17, 2020, converted into Law n. 27 dated April 24, 2020, shareholders can only attend the assembly through the designated representative (Dario Trevisan, lawyer), pursuant to article 135-undecies of Legislative Decree No. 58 dated February 24, 1998; the designated representative (Dario Trevisan, lawyer) may also be granted proxies and/or sub-proxies pursuant to article 135-novies of Legislative Decree No. 58 dated February 24, 1998, also in deviation from art. 135-undecies, paragraph 4, of the same Decree. All operative details are available at the Company's website www.cassiopea.com in the section 'Investor/Corporate Governance'.

About Cassiopea

Cassiopea is a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia (or AGA) and genital warts. Cassiopea is investing in innovation that is driving scientific advancement in areas that have been largely ignored for decades. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. The Company's strategy is to leverage this expertise to optimize the commercial potential for its products directly or with a partner. For further information on Cassiopea, please visit www.cassiopea.com.

Next events

Annual General Shareholders Meeting	April 29, 2021, Lainate
Jefferies Virtual Global Health Care Conference	June 1-3, 2021
Half-Year Report 2021	July 2021
Investora	September 15-16, 2021, Zurich
Credit Suisse Equity Conference	Mid-November 2021, Zurich
Jefferies Global Health Care Conference	November 16-18, 2021, London

Contact: